Implantable hemodynamic monitor and methods for use therewith

• US 10,045,701 B2
• Filed: 11/06/2012
• Issued: 08/14/2018
• Est. Priority Date: 08/22/2008
• Status: Active Grant

• Current Assignee: Pacesetter Incorporated (Abbott Laboratories Incorporated)
• Original Assignee: Pacesetter Incorporated (Abbott Laboratories Incorporated)
• Inventors: Schecter, Stuart O.
• Primary Examiner(s): Natnithithadha, Navin
• Assistant Examiner(s): Shostak, Andrey
• Application Number:
  US13/670,194
• Publication Number:
  US 20130066181A1
• Time in Patent Office: 2,107 Days
• CPC Class Codes: A61B 5/02116 of pulse wave amplitude A61B5/02225 takes precedence
• CPC Class Codes: A61B 5/02125 of pulse wave propagation time
• CPC Class Codes: A61B 5/0215 by means inserted into the body catheters A61M25/00
• CPC Class Codes: A61B 5/1459 invasive, e.g. introduced into the body by a catheter A61B5/1464 takes precedence

Abstract

Provided herein are implantable systems that include an implantable photoplethysmography (PPG) sensor, which can be used to obtain an arterial PPG waveform. In an embodiment, a metric of a terminal portion of an arterial PPG waveform is determined, and a metric of an initial portion of the arterial PPG waveform is determined, and a surrogate of mean arterial pressure is determined based on the metric of the terminal portion and the metric of the initial portion. In another embodiment, a surrogate of diastolic pressure is determined based on a metric of a terminal portion of an arterial PPG waveform. In a further embodiment, a surrogate of cardiac afterload is determined based on a metric of a terminal portion of an arterial PPG waveform.

Claims

1. For use in an implantable system including an implantable photoplethysmography (PPG) sensor, a method for monitoring mean arterial pressure (MAP) of a patient, comprising:

(a) determining, with a controller, a metric of a terminal portion (Tmetric) of an arterial photoplethysmography (PPG) waveform measured using the implantable PPG sensor, wherein the terminal portion is from a maximum of the arterial PPG waveform to a following minimum of the PPG waveform, wherein the Tmetric is a total relaxation time (TRT), which is a time from a maximum to the following minimum of the arterial PPG waveform;

(b) determining, with the controller, a metric of an initial portion (Imetric) of the arterial PPG waveform measured using the implantable PPG sensor, wherein the initial portion is from a minimum of the arterial PPG waveform to the following maximum of the PPG waveform, wherein the Imetric is an initial acceleration time (IAT), which is a time from a minimum to the following maximum of the arterial PPG signal;

(c) determining, with the controller, a surrogate of MAP based on the metric of the terminal portion and the metric of the initial portion; and

(d) adjusting, with the controller, an electrical therapy delivered to a heart of the patient as a function of the surrogate MAP.

2. The method of claim 1, wherein the arterial PPG waveform comprises an averaged arterial PPG waveform that is produced by averaging a plurality of cardiac cycles of a PPG signal obtained from the implantable PPG sensor.

3. The method of claim 1, further comprising:

repeating steps (a), (b) and (c) from time to time; and

monitoring changes in MAP by monitoring changes in the surrogate of MAP as steps (a), (b) and (c) are repeated from time to time.

4. For use in an implantable system including an implantable photoplethysmography (PPG) sensor, a method for monitoring mean arterial pressure (MAP) of a patient, comprising:

(a) determining, with a controller, a metric of a terminal portion (Tmetric) of an arterial photoplethysmography (PPG) waveform measured using the implantable PPG sensor, wherein the terminal portion is from a maximum of the arterial PPG waveform to a following minimum of the PPG waveform, wherein the Tmetric is a terminal deceleration slope (TDS) or the beginning terminal deceleration slope (BTDS), where the TDS is a downward slope from a maximum to the following minimum of the arterial PPG waveform, and the BTDS is a downward slope from a maximum to the following dicrotic notch of the arterial PPG waveform;

(b) determining, with the controller, a metric of an initial portion (Imetric) of the arterial PPG waveform measured using the implantable PPG sensor, wherein the initial portion is from a minimum of the arterial PPG waveform to the following maximum of the PPG waveform and wherein the Imetric is an initial acceleration slope (IAS), which is an upward slope from a minimum to the following maximum of the arterial PPG waveform;

(c) determining, with the controller, a surrogate of MAP based on the metric of the terminal portion and the metric of the initial portion; and

(d) adjusting, with the controller, an electrical therapy delivered to a heart of the patient as a function of the surrogate MAP.

5. For use in an implantable system including an implantable photoplethysmography (PPG) sensor, a method for monitoring mean arterial pressure (MAP) of a patient, comprising:

(a) determining, with a controller, a metric of a terminal portion (Tmetric) of an arterial photoplethysmography (PPG) waveform measured using the implantable PPG sensor, wherein the terminal portion is from a maximum of the arterial PPG waveform to a following minimum of the PPG waveform, wherein the Tmetric is a terminal deceleration time (TeDT), which is a time from a dicrotic notch to the following minimum of the arterial PPG waveform;

(b) determining, with the controller, a metric of an initial portion (Imetric) of the arterial PPG waveform measured using the implantable PPG sensor, wherein the initial portion is from a minimum of the arterial PPG waveform to the following maximum of the PPG waveform, wherein the Imetric is an initial acceleration time (IAT), which is a time from a minimum to the following maximum of the arterial PPG waveform;

(c) determining, with the controller, a surrogate of MAP based on the metric of the terminal portion and the metric of the initial portion; and

(d) adjusting, with the controller, an electrical therapy delivered to a heart of the patient as a function of the surrogate MAP.